Table 1.
Proliferation markers in relation to outcome after primary radiotherapy in laryngeal cancer patients
|
Author Year |
Marker | Method | Cut‐off | N | Stage | Side | Treatment | Outcome, definition |
Univariate HR/OR (95% CI) |
Multivariate HR/OR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Kwon 2015 12 | Ki‐67 | IHC | >50% | 42 | T1‐2 | Larynx | RT | Residual tumor < 0.5 yrs | = 2.16 (0.40‐11.80) | |
| Rademakers 2015 13 | Ki‐67 | IHC | >10% nuclear | 128 | T2‐4N0‐+ | Larynx | ART | Time to local recurrence | = | |
| Nichols 2012 16 | Ki‐67 | IHC | >10% nuclear | 75 | T1‐2 | Glottic | RT | Time to local recurrence | ↓ 3.37 (1.14‐9.86) | ↓ 4.86 (1.58‐15.00) |
| Wildeman 2009 14 | Ki‐67 | IHC‐TMA | OR per 10% increase, nuclear | 59 | T1‐3N0‐3 | Larynx | RT | Local recurrence < 2 yrs | = 0.71 (0.44‐1.15) | |
| Rafferty 2008 7 | Ki‐67 | IHC | >50% Continuous, nuclear | 50 | T2N0 | Larynx | RT | Local recurrence |
↑ = |
= |
| Ahmed 2008 8 | Ki‐67 | IHC |
>10% nuclear Continuous, nuclear |
24 | T1‐2 | Glottic | RT | Persistence or local recurrence |
↑ 0 (0‐∞)* (trend) ↑ |
|
| Cho 2004 10 | Ki‐67 | IHC‐TMA | >10% nuclear | 123 | T1‐2N0 | Larynx | RT | Time to local recurrence | = 0.47 (0.18 −1.23)* | ↑ 0.17 (0.06‐0.49)* |
| Condon 2002 15 | Ki‐67 | IHC | >20% nuclear | 21 | T1‐2N0 | Glottic | RT | Local recurrence < 1 yrs | = 1.94 (0.32‐11.8)* | |
| Motamed 2001 9 | Ki‐67 | IHC | Continuous, nuclear | 28 | T1aN0 | Glottic | n.s. | Radioresistance, n.s. | ↑ (trend) | |
| Sakata 2000 17 | Ki‐67 | IHC* | ≥50% |
130 51 79 |
T1‐2N0 | Glottic |
RT/ART RT ART |
Local recurrence |
↓ 2.66 (1.17‐6.08)* = 1.32 (0.40‐4.38)* ↓ 5.11 (1.53‐17.04)* |
|
| Kropveld 1998 11 | Ki‐67 | IHC | Continuous | 36 | T2N0‐2 | Larynx | RT | Locoregional recurrence | ↑ | |
| Munck 1993 18 | PCNA | IHC | Continuous, nuclear | 28 | T1N0 | Glottic | RT | Recurrent or persistent, n.s. | ↑ |
*, (Subgroup) analysis performed by authors of this systematic review; “=”, No relation with outcome; ↑, Positivity of marker associated with good outcome; ↓, Positivity of marker associated with poor outcome; ART, accelerated radiotherapy; CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; n.s., not specified; OR, odds ratio; RT, conventional radiotherapy; TMA, tissue microarray; yrs, years.